Welcome to our dedicated page for Klotho Neurosciences news (Ticker: KLTO), a resource for investors and traders seeking the latest updates and insights on Klotho Neurosciences stock.
Klotho Neurosciences, Inc. (NASDAQ: KLTO) is a biogenetics and biotechnology company whose news flow centers on the development of Klotho gene-based cell and gene therapies for neurodegenerative and age-related disorders. Company announcements describe programs built around a protein derived from a patented form of the human “anti-aging” Klotho gene (s-KL), with a focus on conditions such as ALS, Alzheimer’s disease, and Parkinson’s disease, as well as broader longevity-related indications.
News items for KLTO commonly cover pipeline progress, including manufacturing and development updates for gene therapy candidates like KLTO-101 and KLTO-202, and regulatory milestones such as Orphan Drug Designation for KLTO-202 for the treatment of ALS. Releases also highlight strategic partnerships, notably Klotho’s collaboration with AAVnerGene Inc. to use AAVone and ATHENA platforms for AAV-based manufacturing and tissue-targeted delivery of Klotho gene therapies.
Investors following KLTO news will also see corporate and financing developments, including capital raises, preferred stock transactions described in the company’s S-1 registration statement, and Nasdaq listing and compliance updates. Strategic updates outline Klotho’s efforts to expand beyond neurology into technologies that support healthy brain function, organ health, muscle strength, bone health, and other longevity indicators, as well as its evaluation of complementary longevity-related assets.
Coverage further includes conference participation and scientific engagement, such as presentations at biotech and longevity-focused events and the Inaugural Klotho Conference & Scientific Seminar, where advisors and inventors discuss Klotho gene therapy research. For readers interested in KLTO, this news page aggregates these disclosures so they can review pipeline milestones, partnership announcements, regulatory updates, and strategic communications in one place.
Greenland Mines Ltd (Nasdaq: GRML) completed a corporate rebrand from Klotho Neurosciences and changed its Nasdaq ticker to GRML effective at market open on March 12, 2026.
No shareholder action is required; brokerage holdings will automatically reflect the new symbol. The company will host an investor webcast March 12, 2026 at 4:15 PM ET to discuss its expanded focus on critical minerals development in Greenland and its recent acquisition.
Klotho Neurosciences (Nasdaq: KLTO) will rebrand as Greenland Mines Ltd and change its Nasdaq ticker to GRML effective at market open on March 12, 2026.
The move follows the company's acquisition of Greenland Mines Corp. and control of the Skaergaard Project in Southeast Greenland, described as one of the world’s largest undeveloped palladium, gold and platinum deposits. No shareholder action is required; brokerage positions will update automatically. An investor webcast will be held March 12, 2026 at 4:15 PM ET to discuss the strategic rationale and shareholder benefits.
Klotho Neurosciences (Nasdaq: KLTO) has acquired Greenland Mines Corp., securing control of the Skaergaard Project in Southeast Greenland — an estimated $68 billion in-situ palladium, gold, and platinum resource. The deal closed March 4, 2026; full consideration is payable in convertible preferred stock, and Greenland Mines is expected to own ~93% on an as-converted basis.
The company will operate two divisions: Natural Resources (Skaergaard) and Cell & Gene Therapy (KLTO-202 for ALS). The 2022 NI 43-101 reports 364.37 million tons at 2.17 g/t PdEq (25.4 Moz PdEq total resource). The transaction is expected to be treated as a reverse merger; a name and ticker change is planned in late March 2026.
Klotho Neurosciences (NASDAQ:KLTO) is developing two genomics-based diagnostics for longevity research, including a quantitative DNA methylation assay of the alpha-Klotho gene and a multi-gene "Klotho Clock" combining DNA and mRNA analysis.
The company named Dr. Bret Barnes to lead the program and expects a prototype assay in 2026, aiming to use tests in clinical trial stratification and as a revenue-generating service while building a longitudinal database for AI-driven clock improvements.
Klotho Neurosciences (Nasdaq: KLTO) announced that IP Australia has notified the company and its licensor, Universitat Autonoma de Barcelona, that 18 patent claims for composition and use of the human secreted Klotho protein (s-KL) isoform are to be granted.
The claims cover a muscle-cell specific promoter linked to an s-KL gene sequence for treating motor impairment, plus neuronal/iPSC cell uses and delivery systems including AAV and non-viral vectors with muscle or motor neuron tropism.
Klotho Neurosciences (NASDAQ: KLTO) announced that CEO Dr. Joseph Sinkule will present at the Biotech Showcase 2026 in San Francisco on January 13, 2026 at 11:30 AM PT. The event runs January 12–14, 2026 at the Hilton San Francisco Union Square. Company management will be available for one-on-one investor and partner meetings; meeting requests can be sent to ir@klothoneurosciences.com.
Klotho Neurosciences (NASDAQ: KLTO) was named winner of the 2025 BioTech Breakthrough Award for Cell Therapy Innovation of the Year on November 7, 2025. The company was recognized for its work developing gene and cell therapies using a patented secreted form of the human Klotho gene (s-KL) targeting neurodegenerative and age-related diseases including ALS, Alzheimer’s, and Parkinson’s.
The award highlights Klotho’s focus on therapies that aim to address neuronal aging and deliver durable, disease-modifying benefits.
Klotho Neurosciences (Nasdaq: KLTO) said company leaders, including CEO Dr. Joseph Sinkule, will attend Longevity Biotech 2025 in Boston on October 22–23, 2025. The conference at Wightman Mansion (43 Hawes Street, Brookline/Fenway) brings together biotech, pharma, academia and venture participants to discuss longevity therapeutics.
The company will be available for one-on-one meetings with investors and potential partners; meeting requests should be sent to ir@klothoneurosciences.com. Management emphasized focus on disciplined execution and building collaborations to advance therapeutic programs.
Klotho Neurosciences (Nasdaq: KLTO) announced on October 7, 2025 that its Letter of Intent with Turn Biotechnologies was allowed to expire after evaluation by Klotho's board. The board concluded the proposed transaction did not match the company's long-term strategic plan. Klotho will instead concentrate resources on advancing its Klotho anti-aging protein research pipeline and developing treatments targeting longevity.
The company cited the growing longevity medicine market and aging demographics as rationale for prioritizing its human Klotho protein programs.
Klotho Neurosciences (NASDAQ:KLTO) has signed a Letter of Intent to acquire key assets from Turn Biotechnologies in a cash and stock transaction. The deal includes Turn's ERA platform and eTurna RNA delivery system, along with a significant $300 million partnership with a leading South Korean pharmaceutical company.
The acquisition would bring Turn's cellular reprogramming technology, which uses six RNA molecules including Yamanaka factors, together with Klotho's anti-aging expertise. The combined technologies target multiple therapeutic areas including dermatology, ophthalmology, immunology, osteoarthritis, muscle health, and ALS. Post-acquisition, Klotho plans to rebrand and integrate key Turn Biotechnologies team members.